Johnson Financial Group Inc. Sells 2,264 Shares of Danaher Co. (NYSE:DHR)

Johnson Financial Group Inc. decreased its stake in Danaher Co. (NYSE:DHR) by 53.2% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 1,990 shares of the conglomerate’s stock after selling 2,264 shares during the period. Johnson Financial Group Inc.’s holdings in Danaher were worth $461,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. BKM Wealth Management LLC bought a new stake in Danaher in the fourth quarter worth about $27,000. Wetzel Investment Advisors Inc. bought a new stake in shares of Danaher in the fourth quarter valued at approximately $29,000. Rakuten Securities Inc. bought a new stake in shares of Danaher in the fourth quarter valued at approximately $36,000. Financial Connections Group Inc. bought a new stake in shares of Danaher in the fourth quarter valued at approximately $41,000. Finally, Frazier Financial Advisors LLC bought a new stake in shares of Danaher in the fourth quarter valued at approximately $44,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

DHR stock traded up $1.38 during midday trading on Friday, reaching $262.78. The company had a trading volume of 2,089,037 shares, compared to its average volume of 2,351,652. Danaher Co. has a 1 year low of $182.09 and a 1 year high of $268.98. The company has a market capitalization of $194.64 billion, a P/E ratio of 44.54, a P/E/G ratio of 4.02 and a beta of 0.83. The firm has a 50-day moving average price of $249.96 and a 200-day moving average price of $238.95. The company has a debt-to-equity ratio of 0.31, a current ratio of 1.85 and a quick ratio of 1.51.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.72 by $0.20. Danaher had a net margin of 16.78% and a return on equity of 11.43%. The company had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.62 billion. During the same quarter in the prior year, the company earned $2.36 EPS. The firm’s revenue was down 2.6% on a year-over-year basis. On average, research analysts anticipate that Danaher Co. will post 7.63 earnings per share for the current fiscal year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 26th. Stockholders of record on Friday, June 28th will be paid a $0.27 dividend. The ex-dividend date of this dividend is Friday, June 28th. This represents a $1.08 dividend on an annualized basis and a dividend yield of 0.41%. Danaher’s dividend payout ratio (DPR) is 18.31%.

Insider Activity

In other news, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the sale, the director now owns 116,202 shares of the company’s stock, valued at approximately $28,304,483.16. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, CEO Rainer Blair sold 47,175 shares of the company’s stock in a transaction on Wednesday, April 24th. The shares were sold at an average price of $249.22, for a total transaction of $11,756,953.50. Following the completion of the sale, the chief executive officer now directly owns 115,995 shares in the company, valued at approximately $28,908,273.90. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Alan G. Spoon sold 708 shares of the company’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total transaction of $172,454.64. Following the sale, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. In the last 90 days, insiders sold 172,540 shares of company stock valued at $43,523,481. Corporate insiders own 11.10% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on DHR shares. Raymond James boosted their price target on shares of Danaher from $240.00 to $270.00 and gave the company an “outperform” rating in a research report on Wednesday, January 31st. StockNews.com cut shares of Danaher from a “buy” rating to a “hold” rating in a research note on Wednesday, January 31st. HSBC raised shares of Danaher from a “hold” rating to a “buy” rating and boosted their price objective for the company from $250.00 to $280.00 in a research note on Wednesday, April 17th. Royal Bank of Canada boosted their price objective on shares of Danaher from $254.00 to $282.00 and gave the company an “outperform” rating in a research note on Wednesday, January 31st. Finally, Robert W. Baird boosted their price objective on shares of Danaher from $259.00 to $271.00 and gave the company an “outperform” rating in a research note on Wednesday, April 24th. Six equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $267.31.

Danaher Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.